Wall Street analysts forecast that CVS Health (CVS) will report quarterly earnings of $1.57 per share in its upcoming release, pointing to a year-over-year decline of 29%. It is anticipated that revenues will amount to $92.87 billion, exhibiting an increase of 3.5% compared to the year-ago quarter.The current level reflects an upward revision of 5.1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their ...

Core Viewpoint - CVS Health is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending September 2024, with the actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The earnings report is scheduled for November 6, 2024, and could lead to a stock price increase if the results exceed expectations, while a miss could result in a decline [2]. - The consensus estimate for CVS Health's quarterly earnings is $1.57 per share, reflecting a 29% decrease year-over-year, with expected revenues of $92.87 billion, marking a 3.5% increase from the previous year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised 5.13% higher, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for CVS Health is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -12.28%, suggesting a bearish outlook from analysts [10]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict deviations from consensus estimates, with positive readings being more reliable [5][7]. - Stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have historically shown a nearly 70% chance of delivering a positive surprise [8]. Historical Performance - CVS Health has beaten consensus EPS estimates three out of the last four quarters, with a recent surprise of +5.17% when it reported earnings of $1.83 per share against an expectation of $1.74 [11][12]. Conclusion - CVS Health does not currently appear to be a strong candidate for an earnings beat, and investors should consider other factors when making decisions regarding the stock ahead of the earnings release [15].

In the latest trading session, CVS Health (CVS) closed at $56.25, marking a -1.94% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.16%. Elsewhere, the Dow lost 0.37%, while the tech-heavy Nasdaq added 0.78%.The the stock of drugstore chain and pharmacy benefits manager has fallen by 8.78% in the past month, lagging the Retail-Wholesale sector's loss of 0.07% and the S&P 500's gain of 1.67%.Investors will be eagerly watching for the performance of CVS Health in it ...

CVS Health Corporation (CVS) is scheduled to report third-quarter 2024 results on Nov. 6, before the opening bell.In the last reported quarter, the company’s adjusted earnings of $1.83 exceeded the Zacks Consensus Estimate by 5.17%. CVS Health beat estimates in three of the trailing four quarters and missed in one, the average positive surprise being 2.02%.The Zacks Consensus Estimate for third-quarter revenues is pegged at $92.87 billion, suggesting growth of 3.5% year over year. The consensus estimate for ...

Yiannis Zourmpanos, founder of Yiazou IQ, an AI-driven stock research platform providing all-in-one stock reports. Experience: Previously worked at Deloitte and KPMG in external/internal auditing and consulting. Education: Chartered Certified Accountant, Fellow Member of ACCA Global, with BSc and MSc degrees from U.K. business schools. Investment Style: We focus on GARP/Value stocks—high-quality, reasonably priced businesses with strong moats and significant growth potential. We prioritize fundamentals and ...

Foundation announces $1.5 million in new Health Zones funding and progress through first six months of the programWOONSOCKET, R.I., Oct. 23, 2024 /PRNewswire/ -- The CVS Health® Foundation today announced $1.5 million in new Health Zones funding between Good Samaritan Health Center, Open Hand Atlanta and Uber Health to increase access to comprehensive health care services, medically tailored meals and transportation for patients with chronic diseases. This announcement was made during the company's Project ...

Workers at seven CVS pharmacies in Southern California are now on strike, as they demand better pay and health care and to call out what they describe as the company engaging in bad-faith contract bargaining. The strike began Friday and continued through the weekend, affecting four stores in Los Angeles and three others in Orange County. Striking workers outside a Los Angeles location told customers on Saturday not to cross the picket lines, according to The Associated Press.Melissa Acosta, a pharmacy techn ...

If you buy these stocks, you might be in for serious disappointment when they underperform.Investors flock to healthcare stocks with the idea that they're a somewhat safer way of getting a return. After all, medical spending is typically obligatory rather than optional, so the sector probably has a better shot at holding up in the face of a recession than others. And healthcare doesn't have complicating factors like cyclicality that make timing an investment more challenging.But as you probably recognize al ...

CVS Health on Friday replaced CEO Karen Lynch with David Joyner, a CVS veteran who retired before returning to the company last year, after investors including activist Glenview Capital pressured the company to improve its stagnant share price.It also withdrew its 2024 forecast and gave an outlook for third-quarter earnings far below analyst estimates.CVS shares were down 7% at $58.64 on Friday. 3 CVS shares dropped on Friday as it replaced CEO Karen Lynch, who took over in 2021. APThey are down by nearl ...

CVS has replaced CEO Karen Lynch as it struggles to repair its healthcare business.David Joyner, president of the company’s pharmacy benefit management unit Caremark, has been appointed as the new chief executive, CVS announced Friday (Oct. 18).“The board believes this is the right time to make a change, and we are confident that David is the right person to lead our company for the benefit of all stakeholders, including customers, employees, patients, and shareholders,” Roger Farah, executive chairman of t ...